Johnathan Engh, MD

Associate Professor
Director, Neuroendoport Surgery Program
Director, Adult Neurosurgical Oncology

Johnathan Engh




Johnathan Engh, MD, joined the University of Pittsburgh Department of Neurological Surgery in 2008 as an assistant professor and director of the Neuroendoport Surgery Program after completing the department’s seven-year residency program. He subsequently built this program into a national referral center for deep-seated brain tumors and colloid cysts.

Dr. Engh became the director of adult neurosurgical oncology at the University of Pittsburgh in 2014. He was promoted to associate professor in 2014 and he received a secondary appointment as associate professor in the Department of Radiation Oncology in 2016.

Dr. Engh’s primary medical staff appointments are at UPMC Shadyside and UPMC Presbyterian Hospitals, but he also has consulting privileges at Children’s Hospital of Pittsburgh of UPMC, Magee-Womens Hospital of UPMC and UPMC Passavant. In addition, he provides outpatient consulting services via telemedicine at UPMC Bedford and UPMC Northwest.

Originally from northern Virginia, Dr. Engh is a graduate of Duke University and the University of Virginia Medical School.

Dr. Engh’s clinical focus is on neurosurgical oncology, especially minimally invasive operations for central nervous system tumors and intraventricular lesions. From a research perspective, his major interests are the development of minimally invasive tools for cranial surgery and surgical trials for the treatment of brain tumors.

See also: Dr. Engh Receives ACES Award

Specialized Areas of Interest

CNS tumors, minimally invasive surgery, neurosurgical technology and innovation.

Board Certifications

American Board of Neurological Surgery

Hospital Privileges

Children’s Hospital of Pittsburgh of UPMC
Magee-Womens Hospital of UPMC 
UPMC Passavant
UPMC Presbyterian
UPMC Shadyside

Professional Organization Membership

Allegheny County Medical Society
Alpha Omega Alpha
American Association of Neurological Surgeons
Congress of Neurological Surgeons
Pennsylvania Medical Society
Society of Neuro-Oncology
University of Pittsburgh Cancer Institute

Education & Training

BS, Biology and Religion, Duke University, 1997
MD, University of Virginia, 2001
Residency, Neurological Surgery, University of Pittsburgh, 2008
Fellowship, Neurosurgical Oncology, University of Pittsburgh, 2007

Honors & Awards

America’s Best Doctors, 2011-17
Pittsburgh’s Best Doctors, 2012-17
UPMC ACES Award, 2014

Selected Publications

Holt DE, Gill BS, Clump DA, Leeman JE, Burton SA, Amankulor NM, Engh JA, Heron DE. Tumor bed radiosurgery following resection and prior stereotactic radiosurgery for locally persistent brain metastasis. Front Oncol 8;5:84, 2015.

Ling D, Vargo JA, Wegner RE, Flickinger JC, Burton S, Engh J, Amankulor N, Quinn AE, Ozhasoglu C, Heron DE. Post-operative stereotactic radiosurgery to the resection cavity for large brain metastases: clinical outcomes, predictors of intracranial failure, and implications for optimal patient selection. Neurosurgery 76(2):150-7, 2015.

Weiner GM, Chivukula S, Chen CJ, Ding D, Engh JA, Amankulor N. Ommaya reservoir with ventricular catheter placement for chemotherapy with frameless and pinless electromagnetic surgical neuronavigation. Clin Neurol Neurosurg 130:61-6, 2015.

Okada H, Butterfield LH, Hamilton RL, Hoji A, Sakaki M, Ahn BJ, Kohanbash G, Drappatz J, Engh J, Amankulor N, Lively MO, Chan MD, Salazar AM, Shaw EG, Potter DM, Lieberman FS. Induction of robust type-1 CD8+ T-cell responses in WHO grade II low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res 15;21(2):286-94, 2015

Chivukula S, Engh J. A Singular Case of Intracranial Sinus Histiocytosis “without” Massive Lymphadenopathy: Isolated Rosai-Dorfman Disease of the Hypothalamus. J Neurol Surg A Cent Eur Neurosurg 76(3):244-8, 2015.

Abhinav K, Pathak S, Richardson RM, Engh J, Gardner P, Yeh FC, Friedlander RM, Fernandez-Miranda JC. Application of High Definition Fiber Tractography (HDFT) in Management of Supratentorial Cavernous Malformations: a combined qualitative and quantitative approach. Neurosurgery 74(6):668-81, 2014.

Luther N, Kondziolka D, Kano H, Mousavi SH, Engh JA, Niranjan A, Flickinger JC, Lunsford LD. Predicting Tumor Control After Resection Bed Radiosurgery of Brain Metastases. Neurosurgery 73(6):1001-6, 2013.

Thirumala P, Lai D, Engh J, Habeych M, Crammond D, Balzer J. Predictive Value of Somatosensory Evoked Potential Monitoring during Resection of Intraparenchymal and Intraventricular Tumors Using an Endoscopic Port. J Clin Neurol 9(4):244-251, 2013.

Faraji AH, Engh JA, Horowitz M, Lunsford LD, Park DM. Multiple discrete aneurysmal subarachnoid hemorrhages during multimodality management of a hypothalamic glioma-case report. Clinical Neurology and Neurosurgery 115(5):632-635, 2013.

McLaughlin N, Prevedello DM, Engh J, Kelly DF, Kassam AB. Endoneurosurgical resection of intraventricular and intraparenchymal lesions using the port techniqueWorld Neurosurg 79(2 Suppl):S18.e1-8, 2013.

A complete list of Dr. Engh's publications can be reviewed through the National Library of Medicine's publication database.

Research Activities

Dilatable port surgery, a new method for minimally invasive brain tumor surgery, has now been established and certified by the Technology and Innovative Practice Committee of the University of Pittsburgh for continued human use. A clinical trial of fluorescein for brain tumor surgery has also been a success. Continued studies examining the radiologic and behavioral effects of varying methods of brain cannulation in animal models are ongoing.

Media Appearances

19-year-old cyst patient
August 17, 2012

Pitt RB hospitalized: Derrick Burns in stable condition
May 24, 2012

Young Stroke Victims
May 11, 2012
WTAE-TV Action News

Surgery through a straw
February 19, 2009
Pittsburgh Tribune-Review

UPMC Videos

Treating Brain Metastases with the Neuroendoport
Brain metastases are often difficult to treat with open surgery. Additionally, these potentially devastating tumors are often inaccessible. Pioneered at UPMC, the Neuroendoport® is a minimally invasive tool that allows for greater access to brain metastases with lower risk of morbidity and complications

Neuroendoport® for Brain Tumors
Dr. Engh discusses the benefits of Neuroendoport® surgery to remove brain tumors